Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
(READY-4 Trial)

Recruiting in Palo Alto (17 mi)

+29 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Q-Med AB

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Research Team

Eligibility Criteria

Inclusion Criteria

- Male or female at least 18 years of age.

Treatment Details

Interventions

QM1114-DP (Neuromodulator)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: QM1114-DP in the LCL and the GL areasExperimental Treatment1 Intervention

The investigational product (QM1114-DP) is a BoNT Type A. At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines.